assessing-cellular-target-engagement-shp2-ptpn11-phosphatase

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

The Src-homology 2 (SH2) domain-containing phosphatase 2 (SHP2), encoded by the PTPN11 proto-oncogene, is a key mediator of receptor tyrosine kinase ...

Sanford Burnham Prebys Medical Discovery Institute

The nonreceptor protein-tyrosine phosphatase (PTP) SHP2 is encoded by the proto-oncogene  and is a ubiquitously expressed key regulator of cell signaling, acting on a number of cellular processes and components, including the Ras/Raf/Erk, PI3K/Akt, and JAK/STAT pathways and immune checkpoint receptors. Aberrant SHP2 activity has been implicated in all phases of tumor initiation, progression, and metastasis. Gain-of-function  mutations drive oncogenesis in several leukemias and cause developmental disorders with increased risk of malignancy such as Noonan syndrome. Until recently, small molecule-based targeting of SHP2 was hampered by the failure of orthosteric active-site inhibitors to achieve selectivity and potency within a useful therapeutic window. However, new SHP2 allosteric inhibitors with excellent potency and selectivity have sparked renewed interest in the selective targeting of SHP2 and other PTP family members. Crucially, drug discovery campaigns focusing on SHP2 would greatly benefit from the ability to validate the cellular target engagement of candidate inhibitors. Here, we report a cellular thermal shift assay that reliably detects target engagement of SHP2 inhibitors. Using this assay, based on the DiscoverX InCell Pulse enzyme complementation technology, we characterized the binding of several SHP2 allosteric inhibitors in intact cells. Moreover, we demonstrate the robustness and reliability of a 384-well miniaturized version of the assay for the screening of SHP2 inhibitors targeting either WT SHP2 or its oncogenic E76K variant. Finally, we provide an example of the assay's ability to identify and characterize novel compounds with specific cellular potency for either WT or mutant SHP2.

Maria Celeridad

Cancer Metabolism & Signaling Networks Program,
NCI-Designated Cancer Center,
Cancer Metabolism & Signaling Networks Program, NCI-Designated Cancer Center

Sanford Burnham Prebys Medical Discovery Institute

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Maria Celeridad

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Cancer Metabolism & Signaling Networks Program,NCI-Designated Cancer Center,Cancer Metabolism & Signaling Networks Program, NCI-Designated Cancer Center

Sanford Burnham Prebys Medical Discovery Institute

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Cancer Metabolism & Signaling Networks Program,
NCI-Designated Cancer Center,
Cancer Metabolism & Signaling Networks Program, NCI-Designated Cancer Center